Role of High-Risk Human Papillomavirus Infection in Oral Epithelial Dysplasia

2012 ◽  
Vol 114 (5) ◽  
pp. e52
Keyword(s):  
Human Papillomavirus ◽  
High Risk ◽  
Epithelial Dysplasia ◽  
Oral Epithelial Dysplasia ◽  
Human Papillomavirus Infection ◽  
Papillomavirus Infection ◽  
Oral Epithelial

Histologic variation in high grade oral epithelial dysplasia when associated with high-risk human papillomavirus

2017 ◽  
Vol 123 (5) ◽  
pp. 566-585 ◽  
Author(s):  
Sujita Khanal ◽  
Patrick J. Trainor ◽  
Maryam Zahin ◽  
Shin-je Ghim ◽  
Joongho Joh ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
High Risk ◽  
Epithelial Dysplasia ◽  
High Grade ◽  
Oral Epithelial Dysplasia ◽  
Oral Epithelial

scholarly journals SAVER: sodium valproate for the epigenetic reprogramming of high-risk oral epithelial dysplasia—a phase II randomised control trial study protocol

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Caroline McCarthy ◽  
Joseph Sacco ◽  
Stefano Fedele ◽  
Michael Ho ◽  
Stephen Porter ◽  
...  
Keyword(s):  
High Risk ◽  
Sodium Valproate ◽  
Study Protocol ◽  
Epigenetic Reprogramming ◽  
Epithelial Dysplasia ◽  
Phase Iii ◽  
Cancer Development ◽  
Randomised Control Trial ◽  
Oral Epithelial Dysplasia ◽  
Oral Epithelial

Abstract Background Sodium valproate (VPA) has been associated with a reduced risk of head and neck cancer development. The potential protective mechanism of action is believed to be via inhibition of histone deacetylase and subsequent epigenetic reprogramming. SAVER is a phase IIb open-label, randomised control trial of VPA as a chemopreventive agent in patients with high-risk oral epithelial dysplasia (OED). The aim of the trial is to gather preliminary evidence of the clinical and biological effects of VPA upon OED and assess the feasibility and acceptability of such a trial, with a view to inform a future definitive phase III study. Methods One hundred and ten patients with high-risk OED will be recruited from up to 10 secondary care sites in the UK and randomised into either VPA or observation only for 4 months. Women of childbearing potential will be excluded due to the teratogenic properties of VPA. Tissue and blood samples will be collected prior to randomisation and on the last day of the intervention/observation-only period (end of 4 months). Clinical measurement and additional safety bloods will be taken at multiple time points during the trial. The primary outcome will be a composite, surrogate endpoint of change in lesion size, change in grade of dysplasia and change in LOH profile at 8 key microsatellite regions. Feasibility outcomes will include recruitment targets, compliance with the study protocol and adverse effects. A qualitative sub-study will explore patient experience and perception of the trial. Discussion The current management options for patients with high-risk OED are limited and mostly include surgical resection and clinical surveillance. However, there remains little evidence whether surgery can effectively lead to a notable reduction in the risk of oral cancer development. Similarly, surveillance is associated with concerns regarding delayed diagnosis of OED progressing to malignancy. The SAVER trial provides an opportunity to investigate the effects of a repurposed, inexpensive and well-tolerated medication as a potential chemopreventive strategy for patients with high-risk OED. The clinical and biological findings of SAVER will inform the appropriateness, design and feasibility of a definitive phase III trial. Trial registration The trial is registered with the European Clinical Trials Database (Eudra-CT 2018-000197-30). (http://www.isrctn.com/ISRCTN12448611). The trial was prospectively registered on 24/04/2018.

scholarly journals Inconclusive role of human papillomavirus infection in breast cancer

2015 ◽  
Vol 10 (1) ◽  
Author(s):  
Yi Zhou ◽  
Jinyuan Li ◽  
Yuting Ji ◽  
Ming Ren ◽  
Bo Pang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Human Papillomavirus ◽  
Human Papillomavirus Infection ◽  
Papillomavirus Infection
Sign in / Sign up

Export Citation Format

Share Document